Cradle Cap (Infantile Seborrheic Dermatitis): Causes, the Malassezia Question, and the Formulation Constraints That Follow

Cradle cap is the scalp form of infantile seborrheic dermatitis. It starts between week 3 and month 2 of life. The scalp at that age is briefly as oily as an adult's. Maternal androgens drive that sebum surge before birth. Corneocytes then fail to shed cleanly and yellow scale binds to the vertex. Most cases clear without treatment by 12 months. The formulation problem sits inside that window, not at the end of it.

Most cradle cap content is written for parents. This page is written for the brand team that has to brief a contract manufacturer. It covers the condition, what the Malassezia data does and does not prove, and where the cosmetic and drug line sits in 4 markets. It then sets out the 6 formulation constraints that follow. Each constraint costs money at 5,000 units, so each one belongs in the brief rather than in a reformulation.

What Is Cradle Cap and How Long Does It Last?

Cradle cap starts between week 3 and month 2 of life and clears in most infants by 12 months. Reported prevalence sits near 10% of infants in the first 3 months. The scale is greasy and adherent, which separates it from the dry flake of a dry scalp. It does not itch, and that single feature separates it from atopic dermatitis in most cases. Poor hygiene does not cause it, and it does not spread to other children. A brand that opens with a hygiene angle is selling against the clinical picture.

Feature	Cradle cap in the first year	What it changes in the brief
Onset	Week 3 to month 2, peak near 3 months	The use window is months, not years
Sites	Vertex, frontal scalp, eyebrows, nasolabial folds, diaper area	One formula for scalp and skin, or two SKUs
Scale	Greasy, yellow, adherent	An oil phase has to come before the wash
Sensation	Not itchy	Parents buy on appearance, not comfort
Prevalence	About 10% of infants in the first 3 months	Steady category, low urgency purchase
Cause	Not hygiene, not contagious	A cleansing claim is honest, and it is the legal ceiling

How Strong Is the Malassezia Link in Infantile Seborrheic Dermatitis?

Malassezia globosa and Malassezia restricta are recovered in more than 80% of seborrheic dermatitis cases, and the same yeasts sit on normal scalps. The genus is lipid-dependent: it cannot build its own fatty acids, so it lives where sebum is. Its lipases split triglycerides, consume the saturated fatty acids, and leave oleic and arachidonic acid on the skin surface. Those free fatty acids irritate and disturb desquamation. That chain is well described in adult seborrheic dermatitis, where the yeast load is high and antifungal treatment works.

Why Presence Does Not Prove Causation

Recovery rates do not separate affected infants from unaffected ones. Published work links the condition to individual susceptibility rather than to yeast load. A formula built to kill the organism is aimed at a target the diagnostic data does not support. A cosmetic cannot make that claim in any case.

What the Antifungal Response Actually Shows

Medicated shampoos do clear cradle cap, and that result carries most of the causal argument. It carries a confound as well. Ketoconazole shampoo lifts scale and removes sebum, and both actions reduce the plaque without any antifungal effect. The infant substrate is also temporary. The sebum surge fades within months, which is why the condition resolves on its own.

Question	What the data shows	What it changes in the brief
Is Malassezia present?	M. globosa and M. restricta in over 80% of cases	Presence is not a target a cosmetic can sell
Is it specific to lesions?	The same yeasts sit on unaffected scalps	Removing the yeast is not the mechanism
Does antifungal treatment work?	Medicated shampoo clears the scale	Scale lift and sebum removal confound the result
Is the infant case adult dandruff?	The infant substrate fades within months	The formula has a short job, then stops mattering

Where Does a Cradle Cap Product Sit on the Cosmetic and Drug Line?

4 markets draw the line in different places, and the words on pack decide which side a product lands on. In the EU, Regulation (EC) No 1223/2009 defines a cosmetic by function. The enumerated functions are cleansing, perfuming, changing appearance, protecting and keeping in good condition. A product presented as treating seborrheic dermatitis falls outside that definition and needs a medicinal authorisation. In the US, a treat claim makes the product a drug under the Federal Food, Drug and Cosmetic Act. The OTC monograph at 21 CFR part 358 lists the recognised anti-dandruff actives, and it contains no infant category.

Europe also closed the classic active route. Regulation (EU) 2021/1902 moved zinc pyrithione to Annex II of the cosmetics regulation, applicable from 1 March 2022. The most widely used anti-dandruff active in the world is therefore prohibited in EU cosmetics, rinse-off included. A cradle cap shampoo built on it cannot be sold in Europe at any claim level.

China arrives at a similar position by another route. The children's cosmetics regulation bars raw materials used for anti-dandruff purposes, so a cradle cap shampoo cannot lean on that function in that market either.

Market	Instrument	Effect on a cradle cap brief
European Union	Regulation (EC) No 1223/2009	A treat claim is medicinal; a cosmetic may cleanse and soften
EU actives	Regulation (EU) 2021/1902, applicable from 1 March 2022	Zinc pyrithione prohibited, rinse-off included
United States	Federal Food, Drug and Cosmetic Act; 21 CFR part 358	A treat claim makes it a drug; no infant category exists
China	儿童化妆品监督管理规定, 2021年第123号, in force 1 January 2022	No medical terms, no anti-dandruff purpose materials
ASEAN	ASEAN Cosmetic Directive	Same split, notification in each member state

Which Formulation Constraints Follow from the Etiology?

A brief built on scale and sebum has 6 constraints, and each one carries a failure mode. The target is not inflammation, so no corticosteroid, no keratolytic and no antifungal enters the formula as a hero. The product has to hydrate adherent scale, hold it long enough to soften, and then take the free lipid away.

Constraint	At the bench	Failure mode
Target	Hydrate and soften adherent scale	A wash alone leaves the plaque in place
Sequence	Oil first, wash second	Oil left on the scalp supplies lipid to the yeast
Occlusion	Short contact on the scalp only	Follicular occlusion where sebum is already active
Keratolytics	No salicylic acid in a leave-on	EU bars under-3 use outside shampoo
Fragrance	None, masking fragrance included	Sensitisation on a scalp that already leaks water
Actives	No antifungal, no implied claim	The product crosses to the drug side

Salicylic acid is the clearest example. EU restriction excludes its use in products for children under 3, shampoo excepted. An anti-scale shampoo can carry it, and a leave-on cream cannot. The exception is legal and still a poor idea on an infant scalp. Keratolysis strips corneocytes from a barrier that is already shedding abnormally.

Fragrance is the second. Regulation (EU) 2023/1545 expanded the declarable allergen list to 81 substances. The thresholds are 0.001% in leave-on and 0.01% in rinse-off products. New products placed on the market from 31 July 2026 must comply. Existing stock may stay on sale until 31 July 2028. A scalp with active scale is the last place to add a sensitiser.

How Should the Softening Oil Be Built?

The oil phase turns on 1 decision: how much oleic acid the carrier brings to the scalp. Malassezia lipases leave oleic acid behind when they split sebum. Oleic acid is the free fatty acid that disrupts stratum corneum lipid organisation. A carrier rich in oleic acid adds to that pool at the same time as it softens the scale. Mineral oil adds nothing to the pool and carries no allergen load.

Carrier	Dominant fatty acid	Lipid supply to Malassezia	Fit for the brief
Mineral oil	None	None	First choice for short contact
Sunflower oil	Linoleic	Low	Acceptable, still a lipid
Olive oil	Oleic, about 75%	High	Avoid on an active scalp
Coconut oil	Lauric	Moderate	Occlusive, use with care

The second decision is contact time. Oil softens adherent scale within the first hour of contact. Leaving it on overnight supplies lipid to a lipophilic yeast for 8 hours. The defensible routine is short contact, then a wash that removes the carrier, then a soft brush on softened scale.

What Changes in the Wash Base?

3 parameters move when a wash is built for scale rather than for skin feel. The surfactant class moves down in aggressiveness, the pH window narrows to 5.0 to 5.5, and foam density stops being a design target. The wash still has to remove the oil applied before it, so mildness cannot go so far that the carrier stays on the scalp.

Glucoside, amino acid and isethionate systems all clear that bar. A sulphate base clears sebum faster and leaves the scalp at a higher pH, which is the wrong trade on an infant. Preservation follows the format. A rinse-off product still needs a challenge test to ISO 11930, because a wet scalp in a wet bathroom is a high-load environment. Tea tree oil is the most common parent fix and belongs nowhere near the brief. It is a fragrance allergen and a sensitiser.

How Do You Prove a Cradle Cap Product Works Without a Drug Claim?

No credible manufacturer runs a leave-on trial on infants under 6 months. The file rests on 4 test types, and each one maps to a claim the brand can defend.

Test	What it answers	Claim it supports
Instrumental scale and hydration grading, 4 weeks	Does visible scale reduce	Softens and lifts scale
Dermatologically scored wash trial	Does daily use irritate	Gentle enough for daily use
HRIPT and patch test	Sensitisation potential	Dermatologically tested
Stability, compatibility, ISO 11930	Does the formula hold and stay safe	Shelf life and pack compatibility

The claim ladder is short. "Treats cradle cap" is a drug claim in the EU and the US. "Helps soften and loosen cradle cap scale" is a cosmetic claim, and it still needs instrumental evidence that scale reduced. The distance between those two sentences is the regulatory strategy of the whole SKU.

What Does a Cradle Cap Brief Cost in Time, MOQ and Test Cycles?

5,000 units is the entry point for a standard pack, and 11 weeks is the realistic path from brief to bulk. Sampling takes 1 week. Each panel takes 4 weeks, and panels run in parallel where the protocol allows. Bulk production takes 6 weeks after sample approval. MOQ sits at 5,000 units for a bottle or tube, 10,000 for an aluminium jar, 50,000 for a mask and 200,000 for an ampoule.

Format changes the path. An anhydrous oil needs no preservative and no challenge test, so it clears the file faster than a cream or a gel. That is why a cradle cap oil is usually the first SKU and the shampoo follows it. A 5,000 unit first batch also lets a brand test an oil and a wash in one market before committing to a second run.

What Should You Ask a Manufacturer Before Briefing a Cradle Cap SKU?

6 questions separate a factory that can fill a baby product from one that can carry a cradle cap brief. The first is infant scalp experience. Ask which existing base is closest and what its test history is. A factory with 5,000 developed formulas answers that from a shelf, not from a proposal.

The second is preservative strategy for a rinse-off that removes oil. The third is fragrance policy, including masking fragrance. The fourth is who signs off claim wording, because the treat claim is a legal decision and not a copy decision. The fifth is the test panel, named in full before the brief is priced. The sixth is MOQ and lead time at that MOQ.

DEVA Skincare runs a 100,000 class GMPC cleanroom, a core laboratory built to CNAS standards, 150 efficacy and safety protocols and 72 inspection steps between raw material release and filling. Two baby SKUs made here each ship about 13 million units a year: a physical sunscreen and an amino acid foam cleanser. The partner behind the sunscreen line was named Asia's number one baby sunscreen brand by Euromonitor in 2024, which is the client's award and not ours.

If a cradle cap oil, shampoo or leave-on cream is on your next launch plan, send the brief through the quote form on this page. DEVA Skincare will come back with a formula direction, a packaging shortlist and a quote at 5,000 units.

What Do Brand Teams Ask About Cradle Cap?

6 questions come up in almost every cradle cap brief, and the answers below are the ones our technical team gives on calls.

Is cradle cap caused by a fungus?

Malassezia yeasts sit on most infant scalps, including scalps with no cradle cap. That makes them a likely contributor rather than a proven cause. The condition tracks individual susceptibility more closely than yeast load, and the sebum surge that feeds the yeast fades within months. A cosmetic cannot claim to act on the organism.

Does cradle cap need an antifungal shampoo?

Not in most cases. Guidance puts emollient and gentle washing first, and most infants clear within weeks without an antifungal. A medicated shampoo is a clinical decision for a persistent or widespread case. In the EU, zinc pyrithione is prohibited in cosmetics, so an antifungal shampoo is a pharmacy product and not an ODM cosmetic.

Can a baby shampoo claim to treat cradle cap?

No. A claim to treat seborrheic dermatitis makes the product a drug in the EU and the US, whatever the ingredient list says. A cosmetic can claim to cleanse, soften and help lift scale. Wording such as treats cradle cap or clears seborrheic dermatitis sits on the drug side in both markets.

Is olive oil safe for cradle cap?

Olive oil is roughly three quarters oleic acid, and oleic acid is the free fatty acid Malassezia leaves behind when it splits sebum. It softens scale and adds to the same pool at the same time. Mineral oil softens scale without fatty acid or allergen load, which is why it fits a cradle cap brief more cleanly.

How long does a cradle cap product take to manufacture?

One week to sample, four weeks per test panel and six weeks for bulk after approval. An anhydrous oil needs no preservative challenge, so it can reach bulk in about eleven weeks. A cream or gel adds that test and rarely lands inside the same window.

What is the MOQ for a cradle cap oil or shampoo?

DEVA Skincare runs 5,000 units for a standard bottle or tube and 10,000 for an aluminium jar. Sampling takes one week and bulk takes six weeks after approval. A 5,000 unit first batch covers two variants in one market, enough to read sell-through on a cradle cap oil and a wash.